-
公开(公告)号:US20050239841A1
公开(公告)日:2005-10-27
申请号:US10997675
申请日:2004-11-24
申请人: Andrew Browning , Jonas Nilsson , Martin Scobie , Johan Angbrant , Rune Ringom
发明人: Andrew Browning , Jonas Nilsson , Martin Scobie , Johan Angbrant , Rune Ringom
IPC分类号: A61K31/405 , A61K31/416 , A61K31/4178 , A61K31/454 , C07D209/12 , C07D401/04 , C07D401/06 , C07D401/12 , C07D403/06 , C07D403/12 , C07D405/04 , C07D405/12 , C07D409/12 , C07D413/12 , C07D417/12 , C07D43/02
CPC分类号: C04B35/632 , C07D209/08 , C07D209/12 , C07D401/04 , C07D401/06 , C07D401/12 , C07D403/06 , C07D403/12 , C07D405/04 , C07D405/12 , C07D409/12 , C07D413/12 , C07D417/12
摘要: The invention relates to compounds of the general formula (I) wherein R0, R1, R2, R3, R4, R5, R6, R7, R8, R9, Ar, and X are as defined in the description, or a pharmaceutically acceptable salt, hydrates, geometrical isomers, racemates, tautomers, optical isomers, N-oxides and prodrug forms thereof. The compounds may be used for the treatment or prophylaxis of disorders related to the MCH1R receptor and for modulation of appetite. The invention also relates to such use as well as to pharmaceutical formulations comprising a compound of formula (I).
摘要翻译: 本发明涉及通式(I)的化合物,其中R 0,R 1,R 2,R 3,R 3, R 4,R 4,R 5,R 6,R 7,R 8, R 9,R 9,Ar和X如说明书中所定义,或其药学上可接受的盐,水合物,几何异构体,外消旋体,互变异构体,旋光异构体,N-氧化物和前药形式。 该化合物可用于治疗或预防与MCH1R受体相关的病症并调节食欲。 本发明还涉及这样的用途以及包含式(I)化合物的药物制剂。
-
公开(公告)号:US20070149600A1
公开(公告)日:2007-06-28
申请号:US11409704
申请日:2006-04-24
申请人: Andrew Browning , Martin Scobie
发明人: Andrew Browning , Martin Scobie
IPC分类号: A61K31/4035 , C07D405/02 , C07D209/44
CPC分类号: C07D209/44 , C07D207/448 , C07D209/48 , C07D491/10
摘要: The invention relates to compounds of the general formula (I) wherein R1, R2, R3, Ar, and X are as defined herein, or a pharmaceutically acceptable salt, hydrates, geometrical isomers, racemates, tautomers, optical isomers, N-oxides and prodrug forms thereof. The compounds may be used for the treatment or prophylaxis of disorders related to the MCH1R receptor and for modulation of appetite. The invention also relates to such use as well as to pharmaceutical formulations comprising a compound of formula (I).
摘要翻译: 本发明涉及通式(I)的化合物,其中R 1,R 2,R 3,R 3,Ar和X如上定义 或其药学上可接受的盐,水合物,几何异构体,外消旋体,互变异构体,旋光异构体,N-氧化物和前药形式。 该化合物可用于治疗或预防与MCH1R受体相关的病症并调节食欲。 本发明还涉及这样的用途以及包含式(I)化合物的药物制剂。
-
公开(公告)号:US20050192339A1
公开(公告)日:2005-09-01
申请号:US10995948
申请日:2004-11-23
申请人: Andrew Browning , Martin Scobie
发明人: Andrew Browning , Martin Scobie
IPC分类号: C07D209/12 , C07D401/06 , C07D403/06 , C07D405/04 , C07D409/06 , C07D409/12 , C07D209/04 , A61K31/405
CPC分类号: C07D409/06 , C07D209/12 , C07D401/06 , C07D403/06 , C07D405/04 , C07D409/12
摘要: The invention relates to compounds of the general formula (I) wherein R1, R2, R3, R4, R5, R6, R7, R8, and X are as defined in the description, or pharmaceutically acceptable salts, hydrates, geometrical isomers, racemates, tautomers, optical isomers, N-oxides and prodrug forms thereof. The compounds may be used for the treatment or prophylaxis of disorders related to the MCH1R receptor and for modulation of appetite. The invention also relates to such use as well as to pharmaceutical formulations comprising a compound of formula (I).
摘要翻译: 本发明涉及通式(I)的化合物,其中R 1,R 2,R 3,R 4, R 5,R 5,R 6,R 7,R 8和X如在 描述或其药学上可接受的盐,水合物,几何异构体,外消旋体,互变异构体,旋光异构体,N-氧化物和前药形式。 该化合物可用于治疗或预防与MCH1R受体相关的病症并调节食欲。 本发明还涉及这样的用途以及包含式(I)化合物的药物制剂。
-
公开(公告)号:US06756377B2
公开(公告)日:2004-06-29
申请号:US09988966
申请日:2001-11-19
申请人: Björn M. Nilsson , Martin Scobie
发明人: Björn M. Nilsson , Martin Scobie
IPC分类号: A61K31497
CPC分类号: C07D241/20
摘要: The invention relates to compounds of the general formula (I) wherein R1, R2 and R3 are as described in the specification, which compounds are ligands to the serotonin 5-HT2c receptor.
摘要翻译: 本发明涉及通式(I)的化合物,其中R 1,R 2和R 3如说明书中所述,该化合物是5-羟色胺5-HT 2C受体的配体。
-
-
-